Docoh
Loading...
Sign up Log in

CLDX Celldex Therapeutics

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Company profile

Ticker
CLDX
Exchange
NASDAQ
Website
www.celldex.com
CEO
Anthony Marucci
Employees
Incorporated
Delaware
Location
New Jersey
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
In Vitro & In Vivo Diagnostic Substances
Ortho Clinical Diagnostics • Idexx Laboratories • Myriad Genetics • Quidel • Lantheus • Neogen • Meridian Bioscience • Oxford Immunotec Global • Lucira Health • Intellia Therapeutics ...
Former names
AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
SEC CIK
0000744218
Corporate docs
IRS number
133191702

CLDX stock data

(
)

News

Pro users get this 30m faster
Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2021
22 Jul 21
Guggenheim Initiates Coverage On Celldex Therapeutics with Buy Rating, Announces Price Target of $66
22 Jul 21
Guggenheim analyst Yatin Suneja initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Buy rating and announces Price Target of $66.
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul 21
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
14 Jul 21
Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate
14 Jul 21

Press releases

Pro users get this 30m faster
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
16 Jul 21
HAMPTON, N.J., July 16, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced the closing of its previously announced underwritten public offering of 6,845,238
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock
13 Jul 21
HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
12 Jul 21
HAMPTON, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $175 million
Thinking about trading options or stock in Celldex Therapeutics, Tesla, Prothena Corp, Microsoft, or Annovis Bio?
12 Jul 21
Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
9 Jul 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

6 May 21
4 Aug 21
31 Dec 21

Financial summary

Financial statements Chart CLDX financial data
Quarter (USD)
 Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 69.31M 69.31M 69.31M 69.31M 69.31M 69.31M
Cash burn (monthly) (positive/no burn) (positive/no burn) 5.55M 5.59M 6.03M 3.86M
Cash used (since last report) n/a n/a 22.95M 23.15M 24.94M 15.99M
Cash remaining n/a n/a 46.36M 46.17M 44.37M 53.32M
Runway (months of cash) n/a n/a 8.4 8.3 7.4 13.8

Beta Read what these cash burn values mean

Recent insider trades

CLDX insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 Jun 21 Marino James J NQSO Common Stock Grant Aquire A No No 28 12,000 336K 12,000
17 Jun 21 Penner Harry JR NQSO Common Stock Grant Aquire A No No 28 12,000 336K 12,000
17 Jun 21 Conrad Herbert J NQSO Common Stock Grant Aquire A No No 28 12,000 336K 12,000
17 Jun 21 Brownlie Keith L NQSO Common Stock Grant Aquire A No No 28 12,000 336K 12,000
17 Jun 21 Shoos Karen L. NQSO Common Stock Grant Aquire A No No 28 12,000 336K 12,000
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

CLDX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

78.9% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 116 128 -9.4%
Opened positions 22 54 -59.3%
Closed positions 34 16 +112.5%
Increased positions 38 32 +18.8%
Reduced positions 37 24 +54.2%
13F shares
 Current Prev Q Change
Total value 1.67B 645.02M +158.7%
Total shares 36.65M 36.81M -0.4%
Total puts 660.3K 408.6K +61.6%
Total calls 1M 592.8K +69.0%
Total put/call ratio 0.7 0.7 -4.4%
Largest owners
 Shares Value Change
RTW Investments 3.91M $80.52M +14.2%
Redmile 3.39M $69.79M +24.9%
Eventide Asset Managment 2.06M $42.49M +12.3%
Cowen Financial Products 2.02M $56.94M NEW
Adage Capital Partners GP, L.L.C. 1.9M $39.14M -24.0%
Wellington Management 1.89M $38.91M +1905.0%
STT State Street 1.88M $38.67M +3.7%
Vanguard 1.8M $37.05M +1.7%
Vivo Capital 1.29M $26.61M 0.0%
VR Adviser 1.24M $25.56M +55.1%
Largest transactions
 Shares Bought/sold Change
Cowen Financial Products 2.02M +2.02M NEW
Wellington Management 1.89M +1.79M +1905.0%
Marshall Wace North America 24.26K -1.26M -98.1%
Boxer Capital 0 -1M EXIT
Ikarian Capital 596.29K -768.7K -56.3%
Redmile 3.39M +676.17K +24.9%
Acuta Capital Partners 1.02M -609.98K -37.5%
Adage Capital Partners GP, L.L.C. 1.9M -600K -24.0%
Renaissance Technologies 541.43K -507.4K -48.4%
Polar Capital 500K -500K -50.0%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Pfizer • Immunomedics • Astrazeneca • Roche • Nektar Therapeutics • Novartis • Stemline Therapeutics • Arrogene • Heat Biologics • Tesaro
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: allergic, amplifying, antihistamine, assertion, AXL, cholinergic, circulating, clear, ColdU, compelling, comprised, contending, CR, cutoff, dermatologic, distribution, downregulated, epinephrine, essence, exercisable, family, FDA, February, Fifteen, follicular, formulation, FricTest, gastrointestinal, greatly, hallmark, hard, hemoglobin, highest, hospitalized, immunosuppression, immunosuppressive, Importantly, intensely, Interferon, intrinsic, introduction, isolated, itch, itching, mAb, marked, marking, meaningful, MerTK, modulate, mononuclear, neuroinflammation, ophthalmic, physician, PN, PR, preliminary, prurigo, pruritic, pts, rapidly, reaction, recovered, respiratory, SCCHN, SD, sensory, settlement, shaking, shortly, stockholder, summer, sweating, temperature, TGFb, threshold, timeline, TME, week
Removed: account, accounted, added, amendment, animal, April, arrangement, ASC, Authority, back, base, Canada, carcinoma, characterize, clarify, confirmation, context, CT, customer, cycle, deducting, deficiency, deterioration, determinable, disclose, documented, dramatic, Duke, enrolled, exam, fall, gastroesophageal, greater, heavily, HNSCC, inducing, induction, instance, lab, lease, lesion, limiting, liver, markedly, median, Merck, month, MSD, node, offset, participant, pharmacological, physical, pre, progressive, readily, RECIST, Refer, release, renal, resolution, River, scan, secure, September, supplement, term, ultimate, undisclosed, unit
From filing 10-Q 2021 Q1

Financial reports

View all
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
29 Mar 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
26 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
7 Mar 19

Current reports

View all
8-K
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
14 Jul 21
8-K
Other Events
12 Jul 21
8-K
Departure of Directors or Certain Officers
1 Jul 21
8-K
Departure of Directors or Certain Officers
17 Jun 21
8-K
Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update
6 May 21
8-K
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results
29 Mar 21
8-K
Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel
4 Jan 21
8-K
Other Events
6 Nov 20
8-K
Celldex Provides Corporate Update and Reports Third Quarter 2020 Results
5 Nov 20
8-K
Other Events
18 Aug 20

Registration and prospectus

View all
424B5
Prospectus supplement for primary offering
14 Jul 21
424B5
Prospectus supplement for primary offering
12 Jul 21
S-8
Registration of securities for employees
16 Jun 21
S-3ASR
Automatic shelf registration
6 Nov 20
S-8
Registration of securities for employees
26 Jun 20
424B5
Prospectus supplement for primary offering
16 Jun 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
12 Jun 20
S-3/A
Shelf registration (amended)
11 Jun 20

Proxies

View all
DEF 14A
Definitive proxy
27 Apr 21
DEF 14A
Definitive proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
7 May 19
DEF 14A
Definitive proxy
26 Apr 19
DEF 14A
Definitive proxy
30 Apr 18
PRE 14A
Preliminary proxy
18 Apr 18
DEF 14A
Definitive proxy
27 Apr 17
PRE 14A
Preliminary proxy
16 Apr 17
DEF 14A
Definitive proxy
20 Apr 16
DEF 14A
Definitive proxy
22 Apr 15

Other

View all
EFFECT
Notice of effectiveness
15 Jun 20
CORRESP
Correspondence with SEC
11 Jun 20
UPLOAD
Letter from SEC
11 Dec 19
CT ORDER
Confidential treatment order
19 Apr 18
EFFECT
Notice of effectiveness
12 Feb 17
EFFECT
Notice of effectiveness
12 Feb 17
CORRESP
Correspondence with SEC
8 Feb 17
CORRESP
Correspondence with SEC
8 Feb 17
UPLOAD
Letter from SEC
5 Feb 17
CORRESP
Correspondence with SEC
11 Jan 17

Ownership

View all
4
Celldex Therapeutics / Freddy A. Jimenez ownership change
21 Jun 21
4
Celldex Therapeutics / Diane C. Young ownership change
21 Jun 21
4
Celldex Therapeutics / Margo Heath-Chiozzi ownership change
21 Jun 21
4
Celldex Therapeutics / Richard M. Wright ownership change
21 Jun 21
4
Celldex Therapeutics / Sarah Cavanaugh ownership change
21 Jun 21
4
Celldex Therapeutics / RONALD PEPIN ownership change
21 Jun 21
4
Celldex Therapeutics / Elizabeth Crowley ownership change
21 Jun 21
4
Celldex Therapeutics / Samuel Bates Martin ownership change
21 Jun 21
4
Celldex Therapeutics / TIBOR KELER ownership change
21 Jun 21
4
Celldex Therapeutics / Anthony S Marucci ownership change
21 Jun 21

Patents

View all
APP
Utility
ANTI-CD27 and ANTI-PD-L1 Antibodies and Bispecific Constructs
1 Jul 21
Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain.
APP
Utility
Agonistic Antibodies That Bind CD40
20 May 21
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
APP
Utility
Use of ANTI-PD-1 Antibody In Combination with ANTI-CD27 Antibody In Cancer Treatment
13 May 21
This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody.
APP
Utility
Anti-MET Antibodies and Methods of Use Thereof
6 May 21
Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET.
APP
Utility
Methods of Treating Cancer with Dendritic Cell Mobilizing Agents
18 Mar 21
Methods of treating cancer comprising administering to patients a dendritic cell mobilizing agent (e.g., Flt3 ligand) in combination with radiation and/or immunoregulatory agents (e.g., checkpoint inhibitors), are disclosed.

Transcripts

View all
2020 Q2
Earnings call transcript
6 Aug 20
2019 Q2
Earnings call transcript
8 Aug 19
2018 Q4
Earnings call transcript
7 Mar 19
2018 Q2
Earnings call transcript
8 Aug 18
2017 Q3
Earnings call transcript
7 Mar 18

Reddit threads

View all